These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Abreu NJ; Waldrop MA Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442 [TBL] [Abstract][Full Text] [Related]
43. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy. Ito M; Ehara Y; Li J; Inada K; Ohno K Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975 [TBL] [Abstract][Full Text] [Related]
44. Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Cynthia Martin F; Hiller M; Spitali P; Oonk S; Dalebout H; Palmblad M; Chaouch A; Guglieri M; Straub V; Lochmüller H; Niks EH; Verschuuren JJ; Aartsma-Rus A; Deelder AM; van der Burgt YE; 't Hoen PA Proteomics Clin Appl; 2014 Apr; 8(3-4):269-78. PubMed ID: 24458521 [TBL] [Abstract][Full Text] [Related]
45. Valley sign in Becker muscular dystrophy and outliers of Duchenne and Becker muscular dystrophy. Pradhan S Neurol India; 2004 Jun; 52(2):203-5. PubMed ID: 15269471 [TBL] [Abstract][Full Text] [Related]
46. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy. Farr GH; Morris M; Gomez A; Pham T; Kilroy E; Parker EU; Said S; Henry C; Maves L Skelet Muscle; 2020 Oct; 10(1):29. PubMed ID: 33059738 [TBL] [Abstract][Full Text] [Related]
47. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9. Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865 [TBL] [Abstract][Full Text] [Related]
48. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. Capitanio D; Moriggi M; Torretta E; Barbacini P; De Palma S; Viganò A; Lochmüller H; Muntoni F; Ferlini A; Mora M; Gelfi C J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):547-563. PubMed ID: 31991054 [TBL] [Abstract][Full Text] [Related]
49. A Systematic Review on the Role of SIRT1 in Duchenne Muscular Dystrophy. Domi E; Hoxha M; Prendi E; Zappacosta B Cells; 2021 Jun; 10(6):. PubMed ID: 34205021 [TBL] [Abstract][Full Text] [Related]
52. Understanding the process of fibrosis in Duchenne muscular dystrophy. Kharraz Y; Guerra J; Pessina P; Serrano AL; Muñoz-Cánoves P Biomed Res Int; 2014; 2014():965631. PubMed ID: 24877152 [TBL] [Abstract][Full Text] [Related]
53. Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients. Anand A; Prabhakar S; Kaul D Neurol India; 1999 Sep; 47(3):218-23. PubMed ID: 10514583 [TBL] [Abstract][Full Text] [Related]
54. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Maruyama R; Yokota T Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217 [TBL] [Abstract][Full Text] [Related]
55. Third case of Duchenne muscular dystrophy and West syndrome: Expanding the spectrum of the DMD neuropsychiatric phenotype. Peña-Padilla C; Romero-Valenzuela I; Baldomero-López A; Sandoval-Talamantes AK; Castellanos-González A; Nagy PL; Kelly RR; Corona-Rivera JR Neuromuscul Disord; 2021 May; 31(5):462-465. PubMed ID: 33741226 [TBL] [Abstract][Full Text] [Related]
57. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. Starosta A; Konieczny P Cell Mol Life Sci; 2021 Jun; 78(11):4867-4891. PubMed ID: 33825942 [TBL] [Abstract][Full Text] [Related]
58. Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases. Kaziród K; Myszka M; Dulak J; Łoboda A Cell Mol Life Sci; 2022 Nov; 79(12):608. PubMed ID: 36441348 [TBL] [Abstract][Full Text] [Related]
59. Abnormal lipid metabolism in skeletal muscle tissue of patients with muscular dystrophy: In vitro, high-resolution NMR spectroscopy based observation in early phase of the disease. Srivastava NK; Yadav R; Mukherjee S; Pal L; Sinha N Magn Reson Imaging; 2017 May; 38():163-173. PubMed ID: 28069416 [TBL] [Abstract][Full Text] [Related]
60. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]